A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents - PubMed

Comparative Study

A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents

D J Heal et al. Br J Pharmacol. 1998 Sep.

Abstract

1. Effects on 5-HT function of sibutramine and its active metabolites, BTS 54 354 and BTS 54 505, were compared with fluoxetine, (+)-fenfluramine and (+)-amphetamine. 2. In vitro sibutramine weakly inhibited [3H]-5-HT uptake into brain synaptosomes. BTS 54 354, BTS 54 505 and fluoxetine were powerful [3H]-5-HT uptake inhibitors, whereas (+)-fenfluramine and (+)-amphetamine were very much weaker. Conversely, whilst sibutramine, its metabolites and fluoxetine did not release [3H]-5-HT from brain slices at < or = 10(-5)M, (+)-fenfluramine and (+)-amphetamine concentration-dependently increased [3H]-5-HT release. 3. Sibutramine and fluoxetine had no effect on 5-hydroxytryptophan (5-HTP) accumulation in either frontal cortex or hypothalamus at doses < 10 mg kg(-1). In contrast, (+)-amphetamine ( > or = 3 mg kg(-1)) reduced 5-HTP in hypothalamus, whilst (+)-fenfluramine (> or =1 mg kg(-1)) decreased 5-HTP in both regions. 4. Sibutramine (10 mg kg(-1) i.p.) and fluoxetine (10 mg kg(-1) i.p.) produced slow, prolonged increases of extracellular 5-HT in the anterior hypothalamus. In contrast, (+)-fenfluramine (3 mg kg(-1) i.p.) and (+)-amphetamine (4 mg kg(-1) i.p.) induced rapid, short-lasting increases in extracellular 5-HT. 5. Only (+)-fenfluramine (10 mg kg(-1)) altered 5-HT2A receptors in rat frontal cortex when given for 14 days, producing a 61% reduction in receptor number and a 18% decrease in radioligand affinity. 6. These results show that sibutramine powerfully enhances central 5-HT function via its secondary and primary amine metabolites; this effect, like that of fluoxetine, is almost certainly mediated through 5-HT uptake inhibition. By contrast, (+)-fenfluramine enhances 5-HT function predominantly by increasing 5-HT release. (+)-Amphetamine, though weaker than (+)-fenfluramine, also enhances 5-HT function by release.

Similar articles

• Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat.

  Jackson HC, Needham AM, Hutchins LJ, Mazurkiewicz SE, Heal DJ. Jackson HC, et al. Br J Pharmacol. 1997 Aug;121(8):1758-62. doi: 10.1038/sj.bjp.0701312. Br J Pharmacol. 1997. PMID: 9283714 Free PMC article.

• Acute cardiovascular effects of sibutramine in conscious rats.

  Woolard J, Bennett T, Dunn WR, Heal DJ, Aspley S, Gardiner SM. Woolard J, et al. J Pharmacol Exp Ther. 2004 Mar;308(3):1102-10. doi: 10.1124/jpet.103.061259. Epub 2003 Nov 21. J Pharmacol Exp Ther. 2004. PMID: 14634034

• Carrier-dependent and Ca(2+)-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine.

  Crespi D, Mennini T, Gobbi M. Crespi D, et al. Br J Pharmacol. 1997 Aug;121(8):1735-43. doi: 10.1038/sj.bjp.0701325. Br J Pharmacol. 1997. PMID: 9283711 Free PMC article.

• Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine.

  Heal DJ, Aspley S, Prow MR, Jackson HC, Martin KF, Cheetham SC. Heal DJ, et al. Int J Obes Relat Metab Disord. 1998 Aug;22 Suppl 1:S18-28; discussion S29. Int J Obes Relat Metab Disord. 1998. PMID: 9758240 Review.

• Progress report on the anorectic effects of dexfenfluramine, fluoxetine and sertraline.

  Garattini S, Bizzi A, Caccia S, Mennini T. Garattini S, et al. Int J Obes Relat Metab Disord. 1992 Dec;16 Suppl 3:S43-50. Int J Obes Relat Metab Disord. 1992. PMID: 1338321 Review.

Cited by

• Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat.

  Axel AM, Mikkelsen JD, Hansen HH. Axel AM, et al. Neuropsychopharmacology. 2010 Jun;35(7):1464-76. doi: 10.1038/npp.2010.16. Epub 2010 Mar 3. Neuropsychopharmacology. 2010. PMID: 20200509 Free PMC article.

• Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus.

  Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J. Norris SL, et al. Cochrane Database Syst Rev. 2005 Jan 25;2005(1):CD004096. doi: 10.1002/14651858.CD004096.pub2. Cochrane Database Syst Rev. 2005. PMID: 15674929 Free PMC article. Review.

• Consumption of palatable food decreases the anorectic effects of serotonergic, but not dopaminergic drugs in baboons.

  Foltin RW. Foltin RW. Physiol Behav. 2011 Jul 6;103(5):493-500. doi: 10.1016/j.physbeh.2011.04.004. Epub 2011 Apr 13. Physiol Behav. 2011. PMID: 21510964 Free PMC article.

• Serotonin release measured in the human brain: a PET study with [¹¹C]CIMBI-36 and d-amphetamine challenge.

  Erritzoe D, Ashok AH, Searle GE, Colasanti A, Turton S, Lewis Y, Huiban M, Moz S, Passchier J, Saleem A, Beaver J, Lingford-Hughes A, Nutt DJ, Howes OD, Gunn RN, Knudsen GM, Rabiner EA. Erritzoe D, et al. Neuropsychopharmacology. 2020 Apr;45(5):804-810. doi: 10.1038/s41386-019-0567-5. Epub 2019 Nov 12. Neuropsychopharmacology. 2020. PMID: 31715617 Free PMC article.

• Effects of low-doses of methamphetamine on d-fenfluramine-induced head-twitch response (HTR) in mice during ageing and c-fos expression in the prefrontal cortex.

  Sun Y, Chebolu S, Skegrud S, Kamali S, Darmani NA. Sun Y, et al. BMC Neurosci. 2023 Jan 11;24(1):2. doi: 10.1186/s12868-022-00766-0. BMC Neurosci. 2023. PMID: 36631757 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central
  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database